Decreased cerebrospinal fluid NDRG2 is associated with non-Alzheimer's disease derived mild cognitive impairment
Authors:
- Qing-Ning ZhangQZQing-Ning Zhang
- Lan-Ke YuLYLan-Ke Yu
- Xin-Yuan ZhangXZXin-Yuan Zhang
- Jia-Lin WuJWJia-Lin Wu
- Si-Yuan SongSSSi-Yuan Song
- Zhao-Hui YaoZYZhao-Hui Yao
- For The Alzheimer'S Disease Neuroimaging InitiativeFIFor The Alzheimer'S Disease Neuroimaging Initiative
- 13 August 2026
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (3) , 1420-1439
Abstract
Background: Mild cognitive impairment (MCI) lacks clear clinical biomarkers. N-Myc downstream-regulated gene 2 (NDRG2) is predominantly localized in astrocytes and is implicated in cognitive function. Objective: This study aims to explore whether cerebrospinal fluid (CSF) NDRG2 could predict MCI and investigate its underlying mechanisms of cognitive decline. Methods: A total of 650 CSF samples were collected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, comprising 157 normal individuals, 366 MCI patients, and 127 Alzheimer's disease (AD) patients. One-way analysis of covariance (ANCOVA) was employed to assess differences in CSF NDRG2 levels among groups. Linear regression was used to analyze the correlation between NDRG2 and amyloid-β (Aβ), phosphorylated tau (p-tau), 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET), albumin quotient (Qalb), and growth-associated protein 43 (GAP43). Receiver operating characteristic (ROC) curves were used to examine the diagnostic performance of NDRG2 for MCI. Results: CSF NDRG2 levels were significantly reduced in MCI, most prominently in non-Aβ and non-tau subgroups. NDRG2 discriminated Aβ-negative MCI with an area under the curve (AUC) of 0.719, but showed limited discriminatory capacity in Aβ+, tau+, and apolipoprotein E ε4 ( APOE ε4) carrier groups. Furthermore, CSF NDRG2 levels were positively correlated with GAP-43, a marker of synaptic plasticity. Conclusions: The present study demonstrates that NDRG2 is a potential biomarker for non-AD derived MCI and suggests its involvement in synaptic plasticity impairment.Keywords
Funding Information
- Hubei Provincial Health and Health Technology Project (WJ2025M007)
- The Medical Scientific Research Project of Wuhan Municipal Health Commission (WX20C01)
- National Natural Science Foundation of China (82271214)
This publication has 56 references indexed in Scilit:
- Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the USJAMA Neurology, 2022
- 2021 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2021
- Astrocyte-specific NDRG2 gene: functions in the brain and neurological diseasesCellular and Molecular Life Sciences, 2019
- Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytesGlia, 2019
- Cognitive assessment tools for mild cognitive impairment screeningJournal of Neurology, 2019
- The Diagnosis and Management of Mild Cognitive ImpairmentJAMA, 2014
- Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampusPsychopharmacology, 2012
- Dexamethasone indirectly induces Ndrg2 expression in rat astrocytesJournal of Neuroscience Research, 2011
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Characterization of the Human NDRG Gene Family: A Newly Identified Member, NDRG4, Is Specifically Expressed in Brain and HeartGenomics, 2001